Details of the Drug

General Information of Drug (ID: DMJ8ACF)

Drug Name
ALX-0761
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Phase 1 [1]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
D0B5UH

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-17 (IL17) TTG0MT6 IL17_HUMAN Modulator [2]
Interleukin-25 (IL25) TTVMO5W IL25_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Psoriasis vulgaris
ICD Disease Classification EA90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-17 (IL17) DTT IL17A 2.91E-02 -0.16 -0.69
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02156466) Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
2 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.